Search Results

DAMMAM VALLEY CONCLUDES THE FIRST SEASON OF ITS BIOTECH STARTUPS PROGRAM AT FII 6, WITH PLANS FOR A SECOND SEASON Dammam Valley & its partners officially concluded their first BioTech Startups Program during the 6th edition of the Future Investment Initiative after a one-hour jury panel of top finale & discussion with world-class leaders. "One of our aims at the program is to help create a community of innovators and entrepreneurs of the highest caliber. We contributed to the Kingdom’s active role in the biotech ecosystem as it strives to pin itself on the map of countries leading in investment and innovation in biotechnology." Said Dr. Abdulrahman, the CEO of Dammam Valley. The BioTech Startups Program, the first of its kind in the nation‪ to stimulate the establishment of emerging companies in the field of biotechnology, provides quality training and consulting in the field to mentor national and international cadres in investing in and seeking funding for biotechnology. Through partnering with world-class mentors and training partners including MSD, Illumina, Pfizer, Mayo Clinic, the startups began their 6-month journey through the program. Originally attracting over 130 applicants from 15 countries in its first phase, 70 were qualified to join the program's second phase during which participants attended workshops geared to help them compete and move on to the next phase. After which in the third and pre-final phase 35 startups went through concentrated mentorship sessions with seasoned leaders and experts in the fields of biotechnology and investment, intended to aid them in further developing their startups and bringing them a step closer in succeeding to commercialize their innovations. Which brought us to today's event, the finale of the program, where the six finalists -in no particular order- Novai from London, Nano Fabric from Dammam, Hypoguard Biotechnology from South Africa, Shomool from Riyadh & Houston, Kinimmune, Inc. from Kansas City & Jeddah, and Optima DX from KAUST were invited on stage to present their startups to the panel, where all secured grants totaling up to $500K, with the total investment raised for startups during the program amounting to $12 million. The jury panel of which the startups presented to included His Royal Highness Prince Khalid bin Waleed bin Talal, and their Excellencies Eng. Khaled AlFaleh and Eng. Bandar Alkhorayef, and Ms. Lubna Alolayan who all partook in giving one-on-one mentor sessions to the finalists prior to the final phase. To which Dammam Valley's CEO, Dr. Abdulrahman Al-Olayan, expressed his appreciation for their significant support and contribution, and went on to thanking their organizational partner: Imam Abdulrahman bin Faisal University; their Strategic Sponsor: Saudi Aramco, and program partners: Ministry of Investment, Ministry of Industry and Mineral Resources, Future Investment Initiative, and Sadara Petrochemical Company. Before concluding the event with a few words directed to the winners "Congratulations to the winners and on behalf of Dammam Valley & its partners I wish you all the best. I cannot emphasize enough; your future success is upon you. The key to success is hard work coupled with innovation and commitment, and all our Program participants have an equal chance to succeed provided they commit and implement the knowledge they acquired." The panel members take home message to the startups. Where he then closed with an announcement pertaining the return of the biotech program with a second season, “With the conclusion of the First BioTech Startups Program, we are excited to share that we will soon be announcing the start of the second season of the Biotech Startups Program in February 2023 projecting bigger investments and wider participation”

Dammam Valley/KSA and Arcensus GmbH/Germany announce the establishment of the Saudi-German Genomic Center in Riyadh to perform high-throughput analysis of genetic samples from the GCC region to improve the medical healthcare system Dammam Valley in partnership with other investment partners, and Arcensus GmbH/Germany, announce the establishment of a high-throughput Saudi-German Genomic Center in Riyadh. The Saudi-German Genomic Center will start operationally with immediate action and provides comprehensive genomic diagnostic services for the GCC region based exclusively on the most sophisticated next-generation sequencing technologies. Based on the expertise of a cross-functional, international team of geneticists, medical experts, and data scientists, the Riyadh center will reflect one of the world’s most innovative genetic biotechnology organizations, provide its knowledge to clinical colleagues, collaborate with all medical decision makers, and support the further improvement of the Saudi healthcare infrastructure in line with the Saudi Health Vision 2030. In addition, the partners believe that with the global adoption of Whole Genome Sequencing as the first line of genetic testing, the genomic era will begin in full force and conquer the molecular medicine market in a short period of time. The initiative to establish this state-of-the-art genomic center stems from the Kingdom’s goal to accelerate the implementation of genetic testing for the early diagnosis of diseases, particularly cancer and rare genetic disorders, but also address the preventive element in personalized medicine. The financial investment led by Dammam Valley will enable the partners to penetrate regional markets faster with their innovative solutions. Dr. Abdulrahman Al-Olayan, CEO of Dammam Valley said, “The establishment and short-term opening of such a state-of-the-art genetic center is central part of the Saudi Vision 2030 and a key element to establish knowledge and expertise in the region. Furthermore, it is a crucial element of the continuous improvement of the regional healthcare systems to the benefit of the entire population. All the knowledge we accumulate here will be used in the next step for the strategic development of a dynamic and vital pharmaceutical and biotech scene. We are pleased to have Arcensus GmbH/Germany as an internationally experienced partner at our side. Especially for the Arab world it is a great pleasure to have Dr. Arndt Rolfs, a highly accomplished, experienced and visionary multi-entrepreneur as a partner.” Dr. Arndt Rolfs, Arcensus Founder and CEO, said, “Especially after Dammam Valley’s investment in the company I have founded end of 2020, Arcensus GmbH, it is a logical and purposeful step to go along the path of establishing a regional center for improving genomic diagnostics with such a proven and reliable partner. The Arab countries have the challenge of improving the early and targeted diagnosis of the numerous genetic diseases. But exactly this knowledge, which can be developed here with the local medical partners, can also serve to establish a dynamic and creative regional and, in a further step, international biotech scene. We are extremely pleased to be able to contribute with our knowledge to this success in the coming years.” Under the terms of the agreement, Dammam Valley along with other investors, will make a substantial investment in establishing the Saudi-German Genomic Center. The parties agree that Arcensus will fully operate the center. The integrity of the protected patient data will be maintained, as will the dedicated sales, marketing and life science business activities. About Dammam Valley Established in 2021, Dammam Valley is a semi government Investment company, solely owned by Imam Abdulrahman bin Faisal University, and with a raised capital of 100,000,000 SAR. It strives to be a source and destination for biotechnology innovation and healthcare in the Middle East and is the Nation’s premiere hub for evaluating and incubating biotech innovations. Aiming to stimulate investment, support projects, and forge quality partnerships in the fields of Health & Biotechnology, in addition to focusing on numerous other sustainable investments in various fields of interest. About Arcensus Arcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. The company provides the highest-standard, secure, trusted, and comprehensive diagnostic service based on Whole Genome Sequencing. Arcensus analyses the complete genetic information in human DNA and identifies the predispositions and reasons for unclear symptoms with the help of cutting-edge bioinformatic technology, including artificial intelligence. The interpretation of the genomic data suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life. From our offices in New Jersey – United States, Rostock and Berlin – Germany, a cross-functional team of genetic experts, medical doctors, and data scientists works to make the most sophisticated and best genetic interpretation with medical and health prevention applications accessible to everyone. For more information, visit https://arcensus-diagnostics.com/. Important Notice and Disclaimer This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Arcensus’ actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing and our ability to continue as a going concern, or other factors.

Dammam Valley/KSA to acquire the majority of Arcensus GmbH/Germany to accelerate the global implementation of Whole Genome Sequencing in genetic diagnostics and delivery of breakthrough technologies in genomic bioinformatics Dammam Valley in partnership with other investment partners, supported by the Ministry of Investment, announce to acquire a majority stake in Arcensus GmbH/Germany. Arcensus, founded by Dr. Arndt Rolfs, a multi-entrepreneur in biotechnology, CEO, and founder of several innovative biotech companies, is a digital health and diagnostics company providing comprehensive genomic diagnostic services based on Whole Genome Sequencing. With a cross-functional, international team of geneticists, medical experts, and data scientists, Arcensus, one of the world’s most innovative genetic biotechnology companies, offers its knowledge and bioinformatic expertise in genomic interpretation together with cutting-edge medical and preventive health applications. The management of Arcensus is convinced that with the worldwide implementation of Whole Genome Sequencing as the first line of genomic testing, the genomic era will start quickly and will conquer the molecular medicine market in a short time. The initiative for the take-over comes from the Kingdom’s aim to improve the global speed in implementing genomic testing for the early diagnosis of genetic diseases, mainly cancer and rare genetic disorders. The financial investment led by Dammam Valley will allow Arcensus to speed up the penetration of the worldwide markets with its innovative solutions. It will be the backbone for developing a comprehensive multi-omic strategy. Dr. Abdulrahman Al-Olayan, CEO of Dammam Valley said, “This is an important step in our global healthcare strategy for KSA, as we believe that the early diagnosis and preventive testing based on real-life genomic expertise with Whole Genome Sequencing is a key ingredient to accelerate the development of, and access to, new future treatments. As a leading technology company in genomic testing, Arcensus GmbH, founded by the visionary multi-entrepreneur, Dr. Arndt Rolfs, is best positioned to provide a deep understanding of bioinformatic technologies and data analytics infrastructure needed not only for the Kingdom of Saudi Arabia but for medical research and development efforts across the globe. A key principle of this is to preserve Arcensus´ autonomy. We are delighted that the founder of Arcensus, Dr. Arndt Rolfs, will continue to manage operations, sit on the board and remain a significant shareholder.” Dr. Arndt Rolfs, Arcensus founder and CEO, said, “Dammam Valley will be a tremendous partner for the global expansion to us and shares our vision for building a worldwide healthcare platform in modern preventive medicine as well as early diagnostics of all genetic diseases. This important partnership will allow us to increase the investments in our modern technology and services platform, as well as our knowledge-based data extraction of the genomic data.” Under the terms of the agreement, Dammam Valley along with other investors will make a double-digit million Euro payment on a fully diluted basis. The parties agree Arcensus to continue its current business model, a network of partnerships and overall objectives following the transaction’s closing. The integrity of the proprietary patient data will be maintained, as will the dedicated sales, marketing, and life sciences business activities. About Dammam Valley Established in 2021, Dammam Valley is a semi-government Investment company, solely owned by Imam Abdulrahman bin Faisal University, and with a raised capital of 100,000,000 SAR. It strives to be a source and destination for biotechnology innovation and healthcare in the Middle East and is the Nation’s premier hub for evaluating and incubating biotech innovations. Aiming to stimulate investment, support projects, and forge quality partnerships in the fields of Health & Biotechnology, in addition to focusing on numerous other sustainable investments in various fields of interest. About Arcensus Arcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. The company provides the highest-standard, secure, trusted, and comprehensive diagnostic service based on Whole Genome Sequencing. Arcensus analyses the complete genetic information in human DNA and identifies the predispositions and reasons for unclear symptoms with the help of cutting-edge bioinformatic technology, including artificial intelligence. The interpretation of the genomic data suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life. From our offices in New Jersey – United States, Rostock and Berlin – Germany, a cross-functional team of genetic experts, medical doctors, and data scientists works to make the most sophisticated and best genetic interpretation with medical and health prevention applications accessible to everyone. For more information, visit https://arcensus-diagnostics.com/. Important Notice and Disclaimer This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Arcensus’ actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing and our ability to continue as a going concern, or other factors.

Dammam Valley, represented by the CEO, Dr. Abdulrahman Al-Olayan, signed a memorandum of understanding with Sadu business solutions, represented by the CEO, Dr. Batil Al-Waqaa, on Tuesday, 14\6\2022, where the memorandum aims to explore joint projects, enhance cooperation and exchange experiences in areas of common interest. Then the visitors had the opportunity to tour the new university hospital and specialized biotechnology laboratories. Dammam Valley is sharing a few photos of the MOU signing event and the tour of the CEOs of Dammam Valley and Sadu through the new university hospital and the specialized biotechnology laboratories.

The program will look to unlock the potential of a nascent MENA biotech ecosystem, through development, grants, and mentorship. While only a few players have emerged out of a local biotech ecosystem, the pandemic has raised questions on how technology and innovation can be utilized to elevate our responses and insurance. It’s something that Saudi biotech giant, Dammam Valley, is looking to address with the launch of a first-of-its-kind program for startups operating in-and-around biotech. The aptly named BioTech Startups Program is aiming to not only stimulate the pockets of biotech innovation happening in the kingdom but to connect the ecosystem with startups operating in the same field from across the world, with a view to opening channels of investment while establishing knowledge-sharing. Divided into four stages, the program will offer grants of up to $500K for successful participants, who will also receive mentorship by the likes of Prince Khaled Bin Alwaleed Bin Talal, Eng. Khaled Al-Falih, Eng. Bandar Al-Khorayef, Ms. Lubna Al-Olayan, and several international experts. You can find out more and apply at www.dammamvalley.com.

DAMMAM — Dammam Valley has launched its Biotech Startups Program in partnership with Imam Abdul Rahman Bin Faisal University, Saudi Aramco, the Ministry of Investment, the Ministry of Industry, Future Investment Initiative Institute (FII), and Sadara Petrochemical Company . A first of its kind in the Kingdom, the Biotech Startups Program is designed to stimulate the establishment of startups in biotechnology and aims to foster communication with existing startups from around the world, providing vast investment opportunities, and motivating distinguished talents as they tackle existing challenges in biotechnology. Furthermore, the program aims to transfer and localize some of the latest global technologies while developing applications in line with national biotechnology strategies, in addition to providing quality instruction and consultancy in management to train national and international cadres to invest in biotechnology. The program falls under four stages, the registration of projects and startups, the selection of qualified projects, the development stage, and finally the final selection stage with grants amounting to $500,000. The qualifying candidates will have a chance to receive mentorship from seasoned leaders with extensive experience in business, investment, and decision-making. The latter include Prince Khaled Bin Alwaleed Bin Talal, Eng. Khaled Al-Falih, Eng. Bandar Al-Khorayef, Ms. Lubna Al-Olayan, and several international experts. The program targets startups in biotechnology field that would like to access training, investment, and market. Interested applicants can directly register at the official registration site through (www.dammamvalley.sa). — SG

Dammam Valley has launched the BioTech Startups Programm, in partnership with Imam Abdul Rahman bin Faisal University, Saudi Aramco, the Ministry of Investment, the Ministry of Industry, Future Investment Initiative Institute (FII), and Sadara Petrochemical Company to develop the biotechnology sector in Saudi Arabia. The program aims to encourage the establishment of startups in biotechnology through investment, foster communication with startups in the sector around the world and enable talent to tackle existing challenges. The BioTech Startups program will provide the qualified projects with grants amounting to $500,000, alongside training, mentorship, and investment opportunities. Press release: Dammam Valley has launched its BioTech Startups program in partnership with Imam Abdul Rahman bin Faisal University, Saudi Aramco, the Ministry of Investment, the Ministry of Industry, Future Investment Initiative Institute (FII), and Sadara Petrochemical Company. A first of its kind in the kingdom, the BioTech Startups Programme is designed to stimulate the establishment of startups in biotechnology and aims to foster communication with existing startups from around the world, providing vast investment opportunities, and motivating distinguished talents as they tackle existing challenges in biotechnology. Furthermore, the program aims to transfer and localize some of the latest global technologies while developing applications in line with national biotechnology strategies, in addition to providing quality instruction and consultancy in management to train national and international cadres to invest in biotechnology. The program falls under four stages, the registration of projects and startups, the selection of qualified projects, the development stage, and finally the final selection stage with grants amounting to $500,000, where qualifying candidates will have a chance to receive mentorship from seasoned leaders with extensive experience in business, investment, and decision-making. The latter include His Royal Highness Prince Khaled bin Alwaleed bin Talal, His Excellency Eng. Khaled Al-Falih, His Excellency Eng. Bandar Al-Khorayef, Ms Lubna Al-Olayan, and several international experts. The program targets startups in the biotechnology field that would like to access training, investment, and market. Interested applicants can directly register at the official registration site.

Riyadh, October 28, 2021, SPA — Minister of Investment Eng. Khalid bin Abdulaziz Al-Falih affirmed that Dammam Valley Company will be an important element in the ambitious national system that is being developed in the fields of health and biotechnologies. This came in his speech during the inauguration of Dammam Valley Company, owned by Imam Abdulrahman bin Faisal University, on the sidelines of the fifth edition of the Future Investment Initiative (FII5), in the presence of Univethe rsity President, Chairman of the Board of Directors of the company Dr. Abdullah bin Mohammed Al-Rubaish, and CEO of the company Dr. Abdulrahman Al-Olayan. Al-Falih expressed his pride in this achievement and step, noting that the Coronavirus pandemic highlighted the importance of biotechnologies, and the need to push this sector to the top of our national priorities, as well as global priorities. He affirmed that the necessity is urgent, more than ever, to develop and enable the research, development, and innovation system in the fields of health and biotechnology, all over the Kingdom of Saudi Arabia.